PAI-1 Biomarker Detection for Peripartum Cardiomyopathy Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing peripartum cardiomyopathy (PPCM) are inadequate, as they rely on non-specific symptoms and lack reliable biomarkers, leading to delayed diagnosis and inappropriate treatments, with existing biomarkers failing to distinguish PPCM from other cardiomyopathies and being influenced by pregnancy-related changes.
Innovation Solution
Analyzing the level and activity of plasminogen activator inhibitor-1 (PAI-1) and its genotype in a sample from a test subject, comparing these to reference data, to identify individuals with PPCM or at risk for developing PPCM, using PAI-1 inhibitors for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general cardiomyopathy markers are used for diagnosis, then broad cardiomyopathy detection is achieved, but specificity for PPCM is lost as markers are within normal range in PPCM patients
Solution Approach 1:
The patent shifts from using conventional cardiomyopathy markers to measuring PAI-1 levels and genetic polymorphisms (4G/5G at -675 and -844G/A at -844) as diagnostic parameters. This parameter change enables specific identification of PPCM patients where traditional markers fail, as PAI-1 shows elevated levels and specific genetic variants are associated with PPCM susceptibility
Solution Approach 2:
The patent introduces PAI-1 as an intermediary biomarker that connects pregnancy-related physiological changes with PPCM pathogenesis. PAI-1 serves as a mediator between the complex pregnancy immune and hormonal changes and the resulting cardiac dysfunction, providing a measurable link for diagnosis
2Measurement precision
If diagnosis is delayed to confirm PPCM, then diagnostic accuracy improves, but time is lost allowing disease progression and adverse events
Solution Approach 1:
The patent enables preliminary identification of PPCM risk by measuring PAI-1 levels and genetic polymorphisms early in the peripartum period. This preliminary action allows clinicians to suspect PPCM earlier and initiate timely diagnostic workup, preventing disease progression while maintaining diagnostic accuracy through specific biomarker measurement
Solution Approach 2:
The patent establishes a feedback mechanism where PAI-1 level measurement provides immediate diagnostic information about PPCM status. This feedback loop allows rapid confirmation or exclusion of PPCM, reducing diagnostic time while maintaining accuracy through objective biomarker thresholds
3Reliability
If invasive therapies are administered to PPCM patients, then treatment effectiveness for severe cases improves, but unnecessary harm occurs to patients who can recover with non-invasive methods
Solution Approach 1:
The patent enables local quality differentiation in treatment approach by precisely identifying PPCM patients through PAI-1 and genetic markers. This precise identification allows tailoring of treatment intensity to individual patient needs, applying aggressive invasive therapies only to those who truly require them while sparing recoverable patients from unnecessary harm
Data Source
AI summary
The present invention relates to a method for identifying a subject, which has peripartum cardiomyopathy (PPCM) or which has a risk for developing PPCM, wherein the method comprises analyzing the amount and/or activity of plasminogen activator inhibitor-1 (PAI-1); and/or the genotype of the PAI-1 gene. The invention also relates to an inhibitor of PAI-1 for use in the treatment of PPCM. Also a method of treating PPCM in a subject in need of such a treatment, wherein said method comprises administering to said subject an effective amount of an inhibitor of PAI-1 is comprised in the present invention. Moreover, the present invention further relates to the use of a binding molecule for identifying a subject, which has PPCM or which has a risk for developing PPCM, wherein said binding molecule specifically binds to PAI-1.